



Journal of Frontiers in Multidisciplinary Research

Legal Implications of AI in Pharmaceutical Decision-Making

Adriane Fugh-Berman

Department of Pharmaceutical Sciences at the University of Iowa College of Pharmacy, USA

* Corresponding Author: **Imelda T Angeles**

Article Info

E-ISSN: 3050-9726

P-ISSN: 3050-9718

Volume: 06

Issue: 01

January-June 2025

Received: 12-01-2025;

Accepted: 10-02-2025

Published: 15-03-2025

Page No: 09-10

Abstract

The integration of artificial intelligence (AI) in pharmaceutical decision-making has revolutionized drug discovery, clinical trials, regulatory compliance, and patient care. However, AI implementation raises critical legal and ethical concerns, including liability, intellectual property rights, data privacy, and regulatory compliance. This paper explores the legal implications of AI in pharmaceutical decision-making, focusing on existing frameworks and challenges. It highlights the necessity for robust legal structures to address AI-related risks while promoting innovation.

Keywords: Artificial intelligence, pharmaceutical decision-making, legal implications, regulatory compliance, data privacy, liability, intellectual property

1. Introduction

The pharmaceutical industry is increasingly reliant on AI to enhance decision-making processes in drug discovery, personalized medicine, and patient care. AI-driven algorithms analyze vast datasets, predict drug efficacy, and streamline clinical trials. However, the integration of AI in pharmaceutical decision-making presents legal challenges, particularly in data protection, liability, and regulatory oversight. This paper examines these challenges and proposes legal solutions to ensure AI is used responsibly and ethically.

2. Materials and Methods

This study employs a qualitative approach, analyzing legal frameworks, case studies, and regulatory policies from various jurisdictions. Primary sources include legislation such as the General Data Protection Regulation (GDPR), the Health Insurance Portability and Accountability Act (HIPAA), and guidelines from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Secondary sources include academic literature, legal commentaries, and industry reports.

3. Results

The findings reveal that while AI enhances pharmaceutical decision-making, existing legal frameworks are insufficient to address AI-specific challenges. Key findings include:

- Data privacy laws vary across jurisdictions, complicating AI compliance.
 - AI liability remains ambiguous, particularly in cases of incorrect drug recommendations.
 - Intellectual property rights related to AI-generated drug patents are unclear.
 - Regulatory bodies are developing AI-specific guidelines but face challenges in enforcement.
-

4. Discussion

4.1 Data Privacy and Security

AI systems in pharmaceuticals rely on sensitive patient data, making privacy protection paramount. GDPR and HIPAA regulate data security but do not fully address AI's automated decision-making. Ethical concerns arise when AI predicts health outcomes without patient consent. Legal solutions must include enhanced data governance and clear consent mechanisms.

4.2 Liability and Accountability

Determining liability in AI-driven pharmaceutical errors is complex. If AI recommends a faulty treatment, it is unclear whether liability falls on the software developer, the pharmaceutical company, or the medical professional using the AI system. Legal frameworks must define responsibility for AI-generated decisions to protect patients and ensure accountability.

4.3 Intellectual Property Rights

AI-driven drug discovery challenges traditional patent laws. If an AI system designs a novel drug, the question arises: who owns the patent—the AI developer, the pharmaceutical company, or the AI itself? Current patent laws do not recognize AI as an inventor, necessitating legal reform.

4.4 Regulatory Compliance

Regulatory agencies such as the FDA and EMA are developing AI-specific guidelines, but challenges remain in standardizing AI validation and approval processes. The lack of a global regulatory framework creates inconsistencies in AI oversight, affecting international pharmaceutical markets.

5. Conclusion

The integration of AI in pharmaceutical decision-making offers transformative potential but introduces significant legal challenges. Addressing these challenges requires updated regulatory frameworks, clear liability rules, robust data protection laws, and revised intellectual property policies. A balanced legal approach will enable AI-driven advancements while ensuring patient safety and ethical compliance.

6. References

1. European Medicines Agency. Guideline on AI in medicinal product development. 2023.
2. U.S. Food and Drug Administration. Artificial Intelligence and Machine Learning in Drug Development. 2022.
3. General Data Protection Regulation (GDPR). Official Journal of the European Union. 2016.
4. Health Insurance Portability and Accountability Act (HIPAA). U.S. Department of Health & Human Services. 1996.
5. Wiegand T, Krishnan R, Reddy S, et al. AI in healthcare: past, present, and future. *NPJ Digital Medicine*. 2019;2(1):38.
6. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56.
7. Thierer A, O'Sullivan A. AI and the future of pharmaceutical regulation. *J Law Med Ethics*. 2021;49(1):90-102.
8. DeCamp M, Lindvall C. Latent bias and the implementation of artificial intelligence in medicine. *J Am Med Inform Assoc*. 2020;27(12):2020-2023.
9. Reddy S, Fox J, Purohit MP. Artificial intelligence-enabled healthcare delivery. *J R Soc Med*. 2019;112(1):22-28.
10. Parikh RB, Obermeyer Z, Navathe AS. Regulation of predictive analytics in medicine. *Science*. 2019;363(6429):810-812.
11. Froomkin AM, Kerr I, Pineau J. When AIs outperform doctors: confronting the challenges of a tort-induced over-reliance on machine learning. *Ariz L Rev*. 2019;61:33-78.
12. Cohen IG, Amarasingham R, Shah A, Xie B, Lo B. The legal and ethical concerns of algorithmic medicine. *N Engl J Med*. 2020;382(10):981-983.
13. Price WN. Big data and black-box medical algorithms. *Sci Transl Med*. 2018;10(471):eaao5333.
14. Ratti E. AI in drug discovery: a legal perspective. *Biotechnol Law Rep*. 2020;39(2):97-106.
15. European Parliament. The AI Act: New legal framework for artificial intelligence. 2023.